Immunovia receives SEK4.9 Million grant from Swelife Accelerator Innovation Program
The grant supports completion of the development studies of IMMray™ PanCan-d, the first blood-based test for early stage pancreatic cancer to enable increased possibility of successful surgical intervention.LUND, Sweden ― Immunovia announced today it has received a follow-on grant of SEK4.9 million from the Swelife Accelerator Innovation Program to support the last development studies of IMMray™ PanCan-d - the first blood-based test for early detection of pancreatic cancer. These studies are performed in close collaboration with CREATE Health Translational Cancer Center at Lund University.